Clinical Trials for Mesothelioma Patients: Bortezomib and Cisplatin Patient Characteristics

Read about the patient characteristics for a current clinical trial being conducted to study the effects of Bortezomib and Cisplatin for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. This study is being conducted ONLY in the United Kingdom.

Patient Characteristics:

• WHO performance status 0-1

• Life expectancy > 12 weeks

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Absolute neutrophil count > 1,500/mm³

• Platelet count > 100,000/mm³

• Creatinine clearance > 60 mL/min OR > 50 mL/min

• ALT and AST < 2.5 times upper limit of normal (ULN) (< 5 times ULN if liver metastases present)

• Bilirubin < 1.5 times ULN

• No concurrent secondary malignancy except carcinoma in situ of the cervix or adequately treated basal cell skin cancer

• No other malignancy treated within the past 5 years o Melanoma, breast cancer, or hypernephroma treated within the past 5 years and without recurrence are allowed

• No uncontrolled or severe cardiovascular disease, including any of the following: o Myocardial infarction within the past 6 months o New York Heart Association class III-IV heart failure o Uncontrolled angina o Clinically significant pericardial disease or cardiac amyloidosis

• No preexisting peripheral neuropathy

• No known or suspected allergy or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used

• No psychological, familial, sociological, or geographical condition that would preclude protocol compliance

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney